Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, will host a live
conference call and webcast tomorrow, June 24, 2019 to discuss the
results of its successful Phase 2b clinical trial of seltorexant
(MIN-202) in patients with insomnia disorder (see dial-in
information below). The Company plans to issue a press
release detailing top-line results prior to the call.
Conference Call Information:
Minerva Neurosciences will hold a conference call and live audio
webcast on June 24, 2019 at 8:30 a.m. Eastern Time to discuss the
results of this trial. To participate, please dial (877)
312-5845 (domestic) or (765) 507-2618 (international) and refer to
conference ID 1644578. To access the webcast, please go to
https://engage.vevent.com/rt/minervaneurosciencesinc~062419.
The live webcast can also be accessed under “Events and
Presentations” in the Investors and Media section of Minerva’s
website at ir.minervaneurosciences.com. The archived webcast
will be available on the website beginning approximately two hours
after the event for 90 days.
Key Opinion Leaders:
Dr. Thomas Roth
Thomas Roth, Ph.D., founded the Sleep Disorders and Research
Center at the Henry Ford Hospital in Detroit, Michigan in 1978 and
has since served as Director of the Center. Dr. Roth is also a
Professor in the Department of Psychiatry at Wayne State University
School of Medicine in Detroit, and serves as a Clinical Professor
in the Department of Psychiatry at the University of Michigan’s
College of Medicine in Ann Arbor.
Dr. Roth primarily publishes on the epidemiology,
pathophysiology, diagnosis, comorbidity with other disorders, and
treatment of insomnia. His research focuses on sleep loss, sleep
fragmentation, and deviation from sleep processes, including
pharmacological effects and sleep pathologies.
After serving as President of the Sleep Research Society and the
Founding President of the National Sleep Foundation (NSF), Dr. Roth
became Chairman of the National Center on Sleep Disorders Research
Advisory Board at the National Institute of Health. He has also
served on the Board of Directors of the Associated Professional
Sleep Societies (APSS).
In 2002, Dr. Roth received the NSF’s Lifetime Achievement Award
for his accomplishments and contributions to sleep science, sleep
medicine, and public health. He also received a Distinguished
Research Award from the Sleep Research Society as well as the
Nathanial Kleitman Award from the Academy of Sleep Medicine.
Dr. Roth is the past Editor-in-Chief of the journal Sleep. He
currently sits on the editorial boards of Sleep Reviews, Stress
Medicine, Advances in Therapy, and Human Psychopharmacology. Dr.
Roth has published over 525 manuscripts, 13 edited volumes, 250
chapters, and 621 abstracts.
Dr. David Kupfer
David J. Kupfer, M.D., is Distinguished
Professor Emeritus, Department of Psychiatry, University of
Pittsburgh School of Medicine, and a board member of Minerva
Neurosciences. He received his bachelor’s and M.D. degrees
from Yale University. Following completion of an internship,
Dr. Kupfer continued his postgraduate clinical and research
training at the Yale New Haven Hospital and the National Institute
of Mental Health (NIMH). In 1970, he was appointed Assistant
Professor of Psychiatry at Yale University School of
Medicine. Dr. Kupfer joined the faculty at the
University of Pittsburgh in 1973.
From 1983 to 2009, Dr. Kupfer served as Chair of
the Department of Psychiatry at the University of Pittsburgh School
of Medicine, and Director of Research at Western Psychiatric
Institute and Clinic. Under Dr. Kupfer's direction, WPIC became one
of the nation's preeminent university-based psychiatric research
centers.
Dr. Kupfer's own research has focused primarily
on sleep physiology, on long-term treatment strategies for
recurrent mood disorders, and on the relationship between
biomarkers and depression. A prolific writer, Dr. Kupfer has
authored or co-authored a combination of more than 1,000 articles,
books, and book chapters, principally focused on sleep and mood
disorders.
He is internationally recognized for his role as
Chair of the American Psychiatric Association Task Force for DSM-5.
In recognition of his contributions to the field, Dr. Kupfer has
been the recipient of numerous awards and honors from professional
societies. In 1990, he was elected to the National Academy of
Medicine (formerly the Institute of
Medicine).
About Seltorexant (MIN-202) Seltorexant is a
selective orexin-2 receptor antagonist under co-development by
Janssen Pharmaceutica N.V., a Pharmaceutical Company of Johnson
& Johnson, and Minerva as adjunctive therapy for Major
Depressive Disorder (MDD) and for the treatment of insomnia
disorder. The orexin system in the brain is involved in the control
of several key functions, including metabolism, stress response and
wakefulness. This system promotes arousal (wakefulness) and is
hypothesized to play a role in excessive arousal, which occurs in
patients with insomnia and in subsets of patients with mood
disorders, and to have clinical utility in the treatment of such
patients.
About Minerva NeurosciencesMinerva
Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of
product candidates to treat CNS diseases. Minerva’s
proprietary compounds include: roluperidone (MIN-101), in clinical
development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in clinical development for insomnia and MDD;
MIN-117, in clinical development for MDD; and MIN-301, in
pre-clinical development for Parkinson’s disease. Minerva’s
common stock is listed on the NASDAQ Global Market under the symbol
“NERV.” For more information, please visit
http://www.minervaneurosciences.com.
Forward-Looking Safe Harbor StatementThis press
release contains forward-looking statements which are subject to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts, reflect management’s
expectations as of the date of this press release, and involve
certain risks and uncertainties. Forward-looking statements
include statements herein with respect to the timing and scope of
current clinical trials and results of clinical trials with
roluperidone, seltorexant, MIN-117 and MIN-301; the timing and
scope of future clinical trials and results of clinical trials with
these compounds; the clinical and therapeutic potential of these
compounds; our ability to successfully develop and commercialize
our therapeutic products; the sufficiency of our current cash
position to fund our operations; and management’s ability to
successfully achieve its goals. These forward-looking
statements are based on our current expectations and may differ
materially from actual results due to a variety of factors
including, without limitation, whether roluperidone, seltorexant,
MIN-117 and MIN-301 will advance further in the clinical trials
process and whether and when, if at all, they will receive final
approval from the U.S. Food and Drug Administration or equivalent
foreign regulatory agencies and for which indications; whether any
of our therapeutic products will be successfully marketed if
approved; whether any of our therapeutic product discovery and
development efforts will be successful; management’s ability to
successfully achieve its goals; our ability to raise additional
capital to fund our operations on terms acceptable to us; and
general economic conditions. These and other potential risks
and uncertainties that could cause actual results to differ from
the results predicted are more fully detailed under the caption
“Risk Factors” in our filings with the Securities and Exchange
Commission, including our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2019, filed with the Securities
and Exchange Commission on May 6, 2019. Copies of reports
filed with the SEC are posted on our website at
www.minervaneurosciences.com. The forward-looking statements in
this press release are based on information available to us as of
the date hereof, and we disclaim any obligation to update any
forward-looking statements, except as required by law.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024